VERTEX PHARMACEUTICALS INC / MA Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) of 5.93 Y for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-01.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm · last filed 2013-03-01
- VERTEX PHARMACEUTICALS INC / MA share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term (deprecated 2012-01-31) for fiscal 2010 was 540.00%.
pure
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) 12 month |
|---|---|
| 2010-12-31 | 540.00% 10-K · filed 2011-02-17 |
Y
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Deprecated 2012-01-31) 12 month |
|---|---|
| 2012-12-31 | 5.93 Y 10-K · filed 2013-03-01 |
| 2011-12-31 | 5.55 Y 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |